Premium
Desferrioxamine in the Treatment of Porphyria Cutanea Tarda: Ineffectiveness of Intramuscular Administration
Author(s) -
Muñoz Juan J.,
GarciaCabezas Juan,
MartinezVerano Juan,
PerezOteyza Carlos,
Salamanca Rafael Enriquez
Publication year - 1990
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/j.1346-8138.1990.tb01651.x
Subject(s) - porphyria cutanea tarda , medicine , phlebotomy , porphyria , deferoxamine , intramuscular injection , excretion , pharmacology
Four patients suffering from porphyria cutanea tarda received intramuscularly 10–15 g per month of desferrioxamine for periods ranging between 21 and 50 months. Porphyrin excretion was serially analyzed during this treatment. Desferrioxamine administration did not induce remission of the disease, which was subsequently achieved after treatment either with phlebotomies or chloroquine. Therefore, chronic intramuscular administration of desferrioxamine alone is ineffective in porphyria cutanea tarda.